The benchmark, called REACH for Rare-cell Evaluation Across Cancer Heterogeneity, is described in Frontiers in Bioinformatics by Moram Venkata Satya Jaswanth, Amruthaluri Gavin, Padarthi Aakash, Muttha Tejesh Kumar, and Abhijit Dasgupta. Rather than asking which method is best in the abstract, REACH formulates rare malignant cell detection as an imbalanced ranking problem. Methods are expected to assign higher scores to high-confidence malignant cells — copy number variation-supported, tumor-intrinsic cells designated P_HC — than to high-confidence background cells designated B_HC, which include immune, stromal, and normal epithelial cells. This malignant-versus-microenvironment contrast deliberately models the circulating tumor cell and minimal residual disease screening regime, and it explicitly excludes the discovery of rare transcriptional substates within an already-malignant population, such as drug-tolerant persisters or cells undergoing epithelial–mesenchymal transition.

What makes REACH unusual is its insistence on reproducibility and multi-track evaluation. The pipeline runs through twelve audited phases, from environment setup to standardized preprocessing, confidence-tiered label construction, benchmark unit generation, method execution under a common wrapper contract, statistical testing, and figure regeneration directly from audited outputs. Every method must produce a continuous cell-level score plus run metadata recording runtime, memory, success or failure status, and degenerate-output flags. Methods that time out or exhaust memory receive fallback random scores that are filtered from aggregation; methods that emit constant or near-constant outputs are retained but flagged. The audited snapshot evaluates ten computational methods on ten curated cancer datasets containing 359,739 cells, producing 11,250 performance measurements across 1,125 benchmark tasks.

The evaluation tracks probe different aspects of method behavior. Track A, the primary endpoint, samples real high-confidence malignant cells into a mock background at four prevalence tiers ranging from 5 percent down to 0.01 percent. Track B applies synthetic Splatter simulations fitted to each real dataset as a secondary stress test. Track C uses background-dominated null controls where no true rare malignant cells are expected, functioning as a specificity pass/fail diagnostic. Track D preserves the natural prevalence of blood and circulating tumor cell datasets. Track E fixes Track A expression matrices while corrupting labels to measure supervised noise sensitivity. A sixth diagnostic track, Track F, masks the global tumor microenvironment contrast entirely and tests whether methods can recover rare malignant epithelial cells hidden among normal epithelial cells of the same tissue origin — a much harder within-lineage problem.

The headline result is a striking gap between supervised and unsupervised performance. A supervised logistic regression trained on 2,000 highly variable genes achieves a median average precision of 1.0 on Track A, indicating that many high-confidence malignant and background labels contain gene expression differences that a supervised model can trivially recover. Current unsupervised methods recover only part of this signal. FiRE, the strongest published inter-lineage detector, reaches a median average precision of 0.313. CaSee, an exploratory cancer/normal cell scorer rather than a dedicated rare-cell detector, reaches 0.512 on all units and 0.606 after excluding 20 degenerate outputs. Statistical testing with a Friedman test and Iman–Davenport correction confirms significant performance differences among methods, and pairwise Wilcoxon tests with Benjamini–Hochberg false discovery rate correction show that FiRE significantly outperforms DeepScena, scCAD, RareQ, and CellSIUS, though not the naive expression threshold baseline or scMalignantFinder.

REACH also reveals strong context dependence. No method performs best across all tumor types. CaSee is the best non-ceiling method on four datasets, the naive expression threshold baseline on two, CellSIUS on one, and scMalignantFinder on one. The supervised ceiling itself collapses on the ovarian cancer ascites dataset, where several unsupervised methods outperform it. This dataset-specific variability justifies reporting method performance in relation to tumor context rather than a single “best method” story, and it cautions against extrapolating leaderboards across cancers.

The null-control Track C results are equally important for interpretation. All eight unsupervised, exploratory, and naive scoring methods control their false-positive rate near the expected 3 percent floor set by the random baseline, and pairwise tests show they are statistically indistinguishable from it. The supervised ceiling is the sole outlier, with a false-positive rate of 0.788 due to in-sample overfitting on all-negative data. This convergence shows that the moderate Track A average precision values of outlier-based methods do not arise from indiscriminate over-flagging of background cells, but from an inability to rank malignant cells above the tumor microenvironment subpopulations these methods legitimately surface as outliers.

The most consequential finding comes from Track F. When the background is restricted to normal epithelial cells of the same lineage, nine of ten methods fall to near-chance average precision at 0.1 percent prevalence. The supervised ceiling itself drops from 1.000 on Track A to 0.001, outputting constant scores because the inter-lineage contrast on which it was trained has been masked. Cluster-decomposition methods such as scCAD show inverted rankings, with mean AUROC significantly below 0.5, indicating that normal epithelial background cells are being ranked systematically above the malignant positives. The sole exception is scMalignantFinder, a pretrained pan-cancer classifier that retains perfect performance — but this result is colorectal-cancer-specific and cannot be generalized. The practical conclusion is stark: methods whose Track A ranking rests on the inter-lineage malignant-versus-microenvironment contrast lose essentially all discriminative power once that contrast is removed.

The authors are careful to frame the supervised ceiling as an inter-lineage separability reference rather than a target that unsupervised rare-cell finders should reach. The near-perfect Track A performance reflects massive inter-lineage expression variance; a lineage-masking scorer comparing epithelial markers against immune and stromal markers would be expected to approach this bound. Three independent lines of evidence — the ceiling’s dataset-specific collapse, its Track F collapse, and its degradation under label noise — indicate that biological separability is the primary driver, with conservative label construction playing a secondary role. The gap between the ceiling and unsupervised methods therefore reflects a real capability gap, not an artifact of label design.

REACH’s limitations are acknowledged openly. The current snapshot relies on infercnvpy as the sole copy number inference arm, though a circularity check confirms that CNV is used purely for labeling and not as a scored comparator, and CNV burden itself discriminates malignant from non-malignant cells with an overall AUROC of 0.782 across 57,811 cells. Track F is restricted to a single colorectal cancer dataset because it is the only one carrying both epithelial cell-type annotations and normal/tumor tissue origin labels. Most datasets use 10× Chromium technology, and spatial transcriptomics and multi-omics data are not yet included. Method stability remains a practical issue, with 249 fallback units and 377 degenerate units recorded across the benchmark. The authors also note that public leaderboards carry overfitting risk and recommend hidden test datasets and containerized execution in future versions.

For clinicians and computational biologists, the message is clear. Inter-lineage leaderboards should not be extrapolated to intra-lineage rare-cell discovery. Detecting drug-tolerant persisters, epithelial–mesenchymal transition intermediates, or emergent resistant subpopulations within an already-identified malignant compartment remains a distinct and currently unsolved problem that will require methods modeling within-lineage structure explicitly rather than global rarity or anomaly. REACH provides a transparent platform for future method comparison and a practical reference for developing more robust malignant cell detection tools — and, on the evidence of this benchmark, extending that reference from the inter-lineage regime to the intra-lineage regime is the more consequential open problem.

Subject of Research: A reproducible benchmark for rare malignant cell detection in single-cell RNA sequencing

Article Title: REACH: a reproducible benchmark for inter-lineage rare malignant cell detection in single-cell RNA sequencing

Article References: Satya Jaswanth, M. V., Gavin, A., Aakash, P., Tejesh Kumar, M., & Dasgupta, A. (2026). REACH: a reproducible benchmark for inter-lineage rare malignant cell detection in single-cell RNA sequencing. Frontiers in Bioinformatics, 6, Article 1878538. https://doi.org/10.3389/fbinf.2026.1878538

Image Credits: AI Generated

DOI: 10.3389/fbinf.2026.1878538

Keywords: single-cell RNA sequencing, rare malignant cell detection, REACH benchmark, computational biology, cancer bioinformatics, tumor microenvironment, circulating tumor cells, minimal residual disease, reproducible benchmarking, machine learning, REACH, reproducible

The starting observation is stark. When tumor cells detach and enter the circulation, most die. They face shear stress from blood flow, a form of programmed cell death called anoikis that kills cells deprived of their normal anchoring, and constant patrolling by immune cells. Only a small fraction survive. But CTCs that travel in clusters fare dramatically better. Previous work has shown that the metastatic potential of CTC clusters is twenty-three to fifty times higher than that of single CTCs, and that approximately ninety-seven percent of metastatic events are mediated by clustered cells rather than lone travelers. These clusters come in several forms: homotypic aggregates of tumor cells sticking to each other, and heterotypic aggregates in which tumor cells bind to platelets, neutrophils, myeloid-derived suppressor cells, or even unusual T cell subsets. Each configuration carries its own protective logic, and the new study argues that understanding that logic is essential before designing drugs to break it.

The platelet component is perhaps the most visually striking. In CTC-positive samples from patients with lung cancer, breast cancer, or melanoma, roughly sixty to eighty-three percent of CTCs are associated with platelet clusters. Platelets adhere to tumor cells through two main mechanisms: P-selectin on the platelet surface recognizes complementary ligands on CTCs, and activated integrin αIIbβ3 binds fibrinogen, which acts as a molecular glue bridging the two cell types. Once attached, platelets confer several advantages. They reduce mechanical injury from shear stress, secrete cytokines that suppress natural killer cell function by lowering expression of the activating receptor NKG2D, induce epithelial-mesenchymal transition through platelet-derived growth factors and TGF-β, and educate CTCs through paracrine signaling to reinforce stem-like phenotypes. Platelet surface PD-L1 can also engage PD-1 on T cells directly, suppressing T cell function and allowing the tumor cell to hide behind a borrowed immunosuppressive shield.

Neutrophils provide a second layer of protection through a different mechanism. CTC surface VCAM-1 binds VLA-4 on neutrophils, and neutrophils respond by releasing neutrophil extracellular traps, or NETs, web-like structures of DNA and antimicrobial proteins that physically capture CTCs and promote cluster formation. Neutrophils also secrete arginase 1, interleukin-10, and reactive oxygen species, which deplete arginine needed for T cell function and directly inhibit T cell and NK cell activation. Enzymes called cathepsin G and elastase released by neutrophils degrade components of the vascular basement membrane, facilitating intravascular migration of CTCs. A particularly unusual partner is the CD4-positive CD8-positive double-positive T cell, a T cell lineage that exhibits immune desensitization upon interaction with CTCs; blocking VLA-4 with neutralizing antibodies disrupts these clusters and prolongs survival in mouse models. Together, platelets and neutrophils form what the authors describe as an immune-protective niche, a mobile microenvironment that travels with the tumor cells and neutralizes the body’s primary defenses.

NNMT enters this picture as a metabolic linchpin. The enzyme catalyzes the conversion of nicotinamide to 1-methylnicotinamide, consuming the universal methyl donor S-adenosylmethionine, or SAM, in the process. This consumption depletes SAM, which alters epigenetic regulation by reducing histone methylation marks such as H3K27me3, and it disrupts NAD-dependent deacetylases like SIRT1. In multiple cancers, high NNMT expression is associated with CTC stemness, chemoresistance, and metastatic potential. In cancer-associated fibroblasts, NNMT promotes H3K27me3 hypomethylation, enhancing complement secretion and recruitment of immunosuppressive myeloid-derived suppressor cells. Pericyte-derived NNMT promotes CTC-neutrophil cluster formation through the CXCL5/CXCR2 axis, and NNMT inhibition has been shown in preclinical models to disrupt these clusters and suppress metastasis. NNMT therefore represents a central node linking metabolic reprogramming and immune evasion in the pre-metastatic niche, and the new study asks whether its activity is coordinated with the platelet and neutrophil programs rather than acting in isolation.

To answer that question, the researchers built a hypothesis-generating computational framework rather than a traditional laboratory experiment. They analyzed bulk RNA sequencing data from 9,596 primary tumor samples across 30 cancer types from the TCGA PanCancer dataset, and cross-validated their findings in eight publicly available single-cell RNA sequencing cohorts representing eight different cancer types, encompassing 483,590 individual cells. They constructed module scores for five biological programs: epithelial-mesenchymal transition and metabolism, platelet and coagulation activity, neutrophil and NET formation, immune checkpoint and exhaustion, and cytotoxic NK cell function. A composite tri-axis score, averaging the first four programs, served as a summary measure of the protective state. Across 29 of 30 TCGA cancer types, NNMT expression was positively correlated with this composite score, with all 29 correlations reaching statistical significance after false discovery rate correction. The median cross-cancer Spearman correlation coefficient for the composite score was 0.500, with the strongest coupling observed in breast cancer, colorectal cancer, melanoma, hepatocellular carcinoma, and lung cancer.

Feature-level pseudotime analysis, which orders cells along a trajectory of increasing NNMT-associated state, showed that the metabolic, platelet, neutrophil, and immune exhaustion programs converged toward a common endpoint, suggesting coordinated activation rather than independent processes. In silico perturbation experiments, in which the researchers computationally reduced NNMT expression to the tenth percentile of its cohort-specific distribution, predicted the largest reductions in the composite protection score in colorectal-cancer stromal cells and lung fibroblasts, followed by breast-cancer CAFs and endothelial cells. This points to stromal and fibroblast-like populations as candidate NNMT-dependent compartments, a finding consistent with prior experimental work showing that NNMT in cancer-associated fibroblasts remodels the tumor microenvironment. Ligand-receptor mapping further revealed an interconnected communication network: CTCs and stromal cells recruit myeloid and NET-forming cells through CXCL5-CXCR2 and VCAM1-ITGA4 signaling, platelet-coagulation bridging forms a protective coating through fibrinogen-αIIbβ3 and P-selectin-PSGL1 interactions, and the myeloid and platelet compartments transmit immunosuppressive signals to T and NK cells through LGALS9-HAVCR2, CD274-PDCD1, PVR-TIGIT, and TGFB1-TGFBR axes.

The authors also applied supervised machine learning to test whether these axis-related features could discriminate single CTCs from clustered or leukocyte-associated CTC states. In a dataset of 281 CTC-labeled cells from GSE109761, a model combining axis features with ligand-receptor features achieved a cross-validated AUROC of 0.711, suggesting that the protective state is detectable at the single-cell level. Cross-cancer generalization was tested using leave-one-cancer-out cross-validation on TCGA data with three-year overall survival as the endpoint, and while the pooled AUROC of 0.575 was modest and unsuitable for diagnosis, the signal was reproducible across cancer types, supporting the idea that the NNMT-associated tri-axis program carries real biological information rather than being an artifact of any single tumor type.

From these findings, the researchers propose a triple-intervention strategy they call disaggregation, exposure, and clearance. The first step uses αIIbβ3 inhibitors such as tirofiban or abciximab, already approved for acute coronary syndromes, to disrupt platelet-CTC adhesion and remove the platelet cloak. The second step uses NNMT inhibitors, which remain in preclinical development, to weaken the metabolic and epigenetic resilience of CTC clusters and potentially reverse epithelial-mesenchymal plasticity, making cells more recognizable to the immune system. The third step deploys PD-1/PD-L1 antibodies to restore T cell and NK cell-mediated clearance of the now-exposed tumor cells. The authors are careful to note that no experimental studies have yet demonstrated the efficacy of combining these three drug classes, and that the synergistic effect between NNMT inhibitors and αIIbβ3 inhibitors currently constitutes a theoretical hypothesis rather than a verified therapeutic regimen.

The study also confronts the risks inherent in such a combination. αIIbβ3 inhibition carries bleeding risk, particularly in cancer patients who may already have low platelet counts, and PD-1/PD-L1 blockade can in rare cases induce immune-mediated thrombocytopenia, potentially compounding the danger. NNMT inhibition is not intrinsically tumor-cell specific, and because NAD salvage and SAM-dependent methylation are also important for T cell and NK cell proliferation and function, systemic NNMT inhibition could theoretically impair the very immune cells the strategy aims to unleash. The authors propose a staged preclinical framework involving phenotypic characterization of patient-derived CTC clusters, multicellular co-culture under physiologically relevant shear flow, immune killing assays, and animal metastasis models, with sequential dosing tested as a design variable rather than assumed to be safe. They also emphasize that CTC clusters represent only one stage of the metastatic cascade, and that even complete clearance of circulating CTCs cannot prevent progression of micrometastatic lesions already established in distant organs. The most appropriate clinical application, they suggest, may be as adjuvant treatment after primary tumor resection in patients at high risk of recurrence, potentially combined with anti-angiogenic agents or stromal modulators targeting micrometastatic niches. Whether the triple strategy can move from computational hypothesis to clinical reality will depend on the experimental validation the authors themselves identify as the critical next step.

Subject of Research: Computational analysis of NNMT-associated metabolic, thromboinflammatory, and immune co-activation in heterogeneous circulating tumor cell clusters

Article Title: NNMT-associated metabolic–thromboinflammatory–immune co-activation in heterogeneous CTC clusters: a hypothesis-generating computational framework”

Article References: Gong, J., Wang, Z., Shi, Y., Ren, M., Li, T., Li, G., & Peng, R. (2026). NNMT-associated metabolic–thromboinflammatory–immune co-activation in heterogeneous CTC clusters: a hypothesis-generating computational framework”. BMC Cancer, 26(1), Article 1085. https://doi.org/10.1186/s12885-026-16692-x

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16692-x

Keywords: circulating tumor cells, CTC clusters, NNMT, metastasis, platelets, neutrophil extracellular traps, immune checkpoint blockade, cancer metabolism, epithelial-mesenchymal transition, single-cell RNA sequencing, TCGA pan-cancer, triple therapy

Researchers at Montpellier University Hospital and Nimes University Hospital conducted a bicentric prospective pilot study, published in BMC Cancer, to test whether circulating tumor cells, or CTCs, could be detected in the peripheral blood of patients during laparoscopic surgery for early-stage cervical carcinoma. The trial, registered on ClinicalTrials.gov as NCT04770090, enrolled eleven patients with histologically confirmed FIGO stage IA1 to IB2 disease, the earliest and most favorable spectrum of cervical cancer. The study was approved by the Ethics Committee IDF11 in Saint-Germain-en-Laye and conducted in accordance with the Declaration of Helsinki, with written informed consent obtained from every participant before inclusion.

The technical centerpiece of the investigation was the CellSearch system, the most clinically validated platform for CTC enumeration in the world. CellSearch exploits a defining biological property of epithelial tumor cells: they express EpCAM, an epithelial cell adhesion molecule, along with cytokeratins, structural proteins of the epithelial cytoskeleton, while lacking CD45, the marker that identifies white blood cells. Blood is drawn into specialized tubes, processed through immunomagnetic enrichment that captures EpCAM-positive cells, and then stained with fluorescent antibodies against cytokeratin and CD45 alongside a nuclear dye. Under automated digital microscopy, a cell is counted as a CTC only if it is nucleated, cytokeratin-positive, CD45-negative, and morphologically consistent with an epithelial tumor cell. This stringent definition is what makes CellSearch the reference standard, capable of finding a single tumor cell among billions of blood cells.

What set this study apart from most liquid biopsy research was its timing protocol. The investigators collected blood at three precisely defined perioperative moments: preoperatively, before any surgical manipulation, designated T0; immediately after creation of the pneumoperitoneum, the carbon dioxide gas inflation of the abdomen required for laparoscopy, designated T1; and just before colpotomy, the surgical opening of the vagina that allows removal of the specimen, designated T2. This three-point sampling design allowed the team to track intraoperative CTC dynamics, asking not merely whether tumor cells circulate in these patients, but whether the surgical process itself changes their numbers.

The results were striking in their pattern. CTCs were detected in three of the eleven patients, a detection rate of 27.3 percent, with a 95 percent confidence interval ranging from 7.3 to 60.7 percent. Crucially, in all three cases the cells appeared only during the operation, never in the preoperative sample. One patient had two CTCs detected at T1, right after pneumoperitoneum creation, while two patients had CTCs detected at T2, before colpotomy, with counts of fifty and two cells respectively. Among the CTC-positive patients, two had epidermoid carcinoma and one had adenocarcinoma, and their disease spanned stages IA1, IA2, and IB1, showing that perioperative cell shedding was not confined to one histological type or one stage within the early spectrum.

The finding that CTCs emerged only intraoperatively, and never preoperatively, carries significant technical and biological weight. It suggests that in these early-stage patients, the baseline burden of circulating tumor cells is so low that even a highly sensitive platform like CellSearch cannot find them before surgery begins. The appearance of cells during the operation raises the possibility that surgical steps, from gas insufflation of the abdomen to manipulation of the tumor-bearing uterus, may dislodge tumor cells into the venous circulation. This echoes a long-standing debate in gynecologic oncology about the potential of minimally invasive surgery to influence tumor cell dissemination, a debate that intensified after major trials questioned the oncological safety of laparoscopy in cervical cancer. The current study does not resolve that controversy, but it provides a direct measurement tool for investigating it at the cellular level.

Histopathological examination of the hysterectomy specimens added another layer of complexity. Residual tumor was found in six of the eleven patients, or 54.5 percent, including one of the CTC-positive patients. After a median follow-up of thirty-four months, one recurrence occurred in the cohort, a rate of 9.1 percent, consistent with the expected recurrence rate for early-stage disease. Notably, the recurrence happened in a patient without perioperative CTC detection, a counterintuitive observation that underscores the preliminary nature of the findings and the danger of drawing prognostic conclusions from such a small sample.

The authors are explicit about the limits of their data. With only eleven patients and a single clinical event, no conclusions can be drawn about the prognostic or therapeutic value of perioperative CTC detection. The wide confidence interval around the detection rate reflects the statistical reality of pilot studies, and the single recurrence in a CTC-negative patient cannot be interpreted as evidence that CTCs are uninformative. What the study does establish is feasibility: the perioperative detection of CTCs in peripheral blood during surgery for early-stage cervical cancer is technically achievable, and the intraoperative dynamics of these cells can be measured with a standardized, reproducible protocol.

The broader significance lies in what this feasibility opens. Liquid biopsy, the analysis of tumor-derived material in blood, has transformed oncology in cancers such as breast, prostate, and colorectal carcinoma, where CTC counts guide prognosis and, in some settings, treatment decisions. Cervical cancer has lagged behind, partly because early-stage disease sheds so few cells that detection platforms struggle to find a signal. By demonstrating that CTCs can be captured during the surgical window itself, the Montpellier and Nimes team has created a methodological foundation for larger prospective cohorts that could ask whether intraoperative cell shedding predicts recurrence, whether it correlates with surgical technique, and whether it could one day inform decisions about adjuvant therapy or follow-up intensity.

For now, the message to patients and clinicians is one of cautious promise. Early-stage cervical cancer remains highly curable, and the vast majority of patients who undergo surgery are cured. This study does not change practice, and its authors emphasize that validation in larger cohorts is essential before any clinical use. But it does change what is measurable. For the first time in this disease, the operating room itself has become a laboratory for observing cancer cells in transit, and the bloodstream has become a window into the earliest moments of a process that may, in a small minority of patients, lead to recurrence. That shift, from retrospective pathology to real-time cellular observation, is the kind of technical advance that quietly reshapes how a disease is understood, and it begins with eleven patients, three blood draws each, and the detection of a handful of cells that no one could see before.

Subject of Research: Cervical cancer

Article Title: Circulating tumor cells detection by liquid biopsy during early-stage cervical cancer surgery: a preliminary feasibility study

Article References: Jeanmart, A., Duraes, M., Francini, S., Rathat, G., Crantelle, L., Duroyon, M. M., Macioce, V., Mollevi, C., Ferrer, C., Cayrefourcq, L., & Alix-Panabires, C. (2026). Circulating tumor cells detection by liquid biopsy during early-stage cervical cancer surgery: a preliminary feasibility study. BMC Cancer. https://doi.org/10.1186/s12885-026-17152-2

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17152-2

Keywords: cervical cancer, liquid biopsy, circulating tumor cells, laparoscopy, surgical oncology, CellSearch, cancer recurrence, gynecology, Circulating, tumor, cells, detection

The research team, led by surgeons from Zhongshan People’s Hospital and Shenzhen Longhua District People’s Hospital in China, analyzed 383 patients who underwent radical resection of solitary HCC with tumors no larger than 5 centimeters. Every patient had preoperative CTC testing performed three days before surgery, using a technique that combines negative immunomagnetic enrichment with immunofluorescence in situ hybridization. In this method, magnetic beads coated with antibodies against CD45—a marker found on white blood cells—are used to strip away leukocytes from a 5-milliliter peripheral blood sample, enriching the rare malignant cells that have entered the bloodstream through epithelial-mesenchymal transition. The remaining cells are then fixed on slides, hybridized with fluorescent probes targeting the centromeres of chromosomes 1 and 8, stained with DAPI, and counted under a fluorescence microscope. A count of one or more CTCs per sample defined CTC-positive status, a threshold the researchers found correlated strongly with microvascular invasion (MVI), the pathological hallmark of tumor aggressiveness in HCC.

The clinical significance of MVI cannot be overstated. From a pathological standpoint, an HCC lesion is not merely the visible tumor mass; it includes microscopic tumor cell nests invading nearby blood vessels, which a narrow resection margin cannot reliably remove. Previous studies have shown that wide margins reduce early postoperative recurrence in patients with MVI, but offer no such advantage in those without it. The problem has been that MVI can only be confirmed definitively after surgery, when the specimen is examined under a microscope—far too late to guide the surgeon’s hand. Imaging-based prediction models exist, but they lack standardized criteria and show limited accuracy, while subjective assessments such as tumor capsule integrity depend heavily on equipment quality and observer judgment. What the new study demonstrates is that CTC status, detectable in a simple blood draw, serves as a preoperative proxy for MVI, and when combined with tumor diameter measured on routine contrast-enhanced CT or MRI, it creates a decision framework that is both objective and minimally invasive.

The statistical architecture of the study was rigorous. All patients were stratified by tumor size (3 centimeters or less versus more than 3 centimeters) and CTC status (positive versus negative), then further divided by margin width—narrow margins defined as less than 1 centimeter and wide margins as 1 centimeter or more, based on the pathologist-reported shortest macroscopic distance from the tumor edge to the line of transection. Kaplan-Meier survival curves and log-rank tests compared recurrence-free survival (RFS) and overall survival (OS) between groups, while univariate and multivariate Cox regression models identified independent risk factors. A landmark analysis with a 24-month cutoff distinguished early from late recurrence, reflecting the understanding that early recurrences arise from residual microscopic disease while late recurrences more often represent de novo tumors in the diseased liver.

The results revealed a striking stratified effect. In the entire cohort, both tumor diameter and CTC status emerged as independent predictors of RFS and OS. But when the researchers drilled into tumor-size subgroups, something unexpected appeared. For patients with tumors 3 centimeters or smaller—179 patients in total—margin width had no effect on RFS or OS, regardless of CTC status. The MVI rate in this group was only 14.5 percent, and based on multicenter pathological data suggesting that MVI lesions extending more than 1 centimeter from the main tumor account for roughly 28 percent of all MVI in small HCC, the researchers calculated that MVI beyond the 1-centimeter threshold likely occurs in fewer than 4 percent of these patients. In other words, a narrow margin is almost always sufficient to clear the microscopic disease in small tumors, and pursuing wider excision offers no survival benefit while sacrificing liver tissue that cirrhotic patients need to preserve.

The picture changed dramatically for patients with tumors larger than 3 centimeters—204 patients in this subgroup. Here, the MVI rate jumped to 43 percent, consistent with prior findings that tumor size predicts both the incidence and the extent of vascular invasion. When the researchers stratified this group by CTC status, the effect of margin width split cleanly. Among CTC-negative patients with larger tumors, narrow and wide margins produced comparable RFS and OS, with no statistically significant difference. But among CTC-positive patients with tumors exceeding 3 centimeters, wide margins yielded significantly better RFS and OS than narrow margins. Moreover, the landmark analysis showed that wide margins in this CTC-positive subgroup specifically reduced early postoperative recurrence—recurrence within 24 months—while having no effect on late recurrence. This finding aligns precisely with the biological mechanism: early recurrences stem from minimal residual disease left behind at the resection margin, and in patients whose tumors are both large and shedding malignant cells into the bloodstream, that residual burden is substantial enough that only a wider excision can remove it.

The correlation between CTC status and MVI held across both tumor-size groups, reinforcing the biological plausibility of the framework. In patients with tumors 3 centimeters or smaller, the CTC-positive rate was 14.5 percent, and CTC-positive status correlated with MVI at a statistically significant level. In the larger-tumor group, the CTC-positive rate rose to 43.1 percent, and the correlation with MVI was even stronger. Notably, CTC status showed no significant association with other clinicopathological variables, including alpha-fetoprotein levels and tumor differentiation grade, suggesting that it captures a distinct dimension of tumor biology—specifically, the propensity for vascular invasion and hematogenous dissemination—that traditional serum markers and histological grading do not fully reflect.

The study’s authors frame their findings within the broader concept of precision medicine in hepatobiliary surgery. By identifying patients who do not need wide margins—those with small tumors regardless of CTC status, and those with larger tumors that are CTC-negative—surgeons can preserve more functional liver parenchyma, reducing the risk of postoperative liver failure and increasing the option of repeat resection or other multimodal therapies if recurrence does occur. Conversely, for the smaller subset of patients with large, CTC-positive tumors, the data argue for pursuing wide margins, or alternatively, for using preoperative adjuvant therapy to reduce tumor burden before attempting an extended resection. Both variables—CTC count from a peripheral blood draw and tumor diameter from standard cross-sectional imaging—are available before the operation, are objective, and involve minimal patient discomfort, making the framework readily implementable in clinical practice without specialized equipment beyond the CTC detection platform.

The researchers acknowledge important limitations. The retrospective design carries inherent biases and confounding factors that only a prospective study with a larger sample size can eliminate. The cohort was overwhelmingly Chinese and hepatitis B virus-related, raising questions about whether the conclusions apply to non-Asian populations or to patients with hepatitis C-related or alcohol-related HCC. CTC counts may fluctuate over time within the same patient, introducing temporal heterogeneity. The median follow-up of 30 months, while adequate for capturing early recurrence patterns, is insufficient for robust long-term overall survival conclusions beyond five years. And the cost of CTC detection remains high in some regions, though the authors expect this to decrease as detection methods improve. The findings also apply specifically to patients with solitary tumors no larger than 5 centimeters, the population in which the resection margin dilemma is most acute.

Despite these caveats, the study represents a meaningful advance in a field where the optimal margin width has been debated for decades without consensus. Previous attempts to stratify patients by tumor size alone produced contradictory results, with some groups reporting survival benefits from wide margins across all tumor diameters and others, including a well-known Hong Kong study, finding no benefit in any subgroup. By adding CTC status as a second, biologically grounded variable, the researchers have created a two-parameter decision tool that resolves those contradictions and matches surgical aggressiveness to the actual risk of microscopic residual disease. For a cancer that kills nearly 800,000 people each year, and where the difference between a narrow and a wide margin can determine whether a patient keeps enough liver to survive the operation—or enough liver to undergo a second operation if the tumor returns—that kind of preoperative clarity is not just a statistical finding. It is a roadmap for safer, more individualized liver cancer surgery.

Subject of Research: Combined analysis of preoperative circulating tumor cells status and tumor size to guide width of resection margin for solitary hepatocellular carcinoma

Article Title: Combined analysis of preoperative circulating tumor cells status and tumor size to guide width of resection margin for solitary hepatocellular carcinoma

Article References: Xie, J., Luo, Q., Huang, D., Xia, F., Wu, Z., Zhou, W., Zhang, Q., Tian, F., Liu, C.-Y., Xu, Z., Jiao, X.-T., Zhang, W.-Q., Ali, M., Zhou, Y., & Gao, H. (2026). Combined analysis of preoperative circulating tumor cells status and tumor size to guide width of resection margin for solitary hepatocellular carcinoma. Frontiers in Oncology, 16, Article 1810914. https://doi.org/10.3389/fonc.2026.1810914

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1810914

Keywords: Combined, analysis, preoperative, circulating, tumor, cells, status, size, guide, width, resection, margin

The team, led by Federica Marocchi and Luisa Lanfrancone, began with an unbiased strategy designed to let the biology speak for itself. Rather than testing candidate genes one by one, they ran functional drop-out screens in patient-derived xenograft models of NRAS-mutant melanoma, systematically silencing genes to see which losses changed the behavior of the tumors in living animals. This approach, which interrogates gene function in a physiologically relevant context rather than in simplified cell culture, singled out MyD88 as a dependency that was selectively required for metastatic progression. That result was unexpected because MyD88 has historically been studied as a scaffold for Toll-like receptor and interleukin receptor signaling in innate immunity, not as a driver of cancer cell behavior.

The most striking finding was the selectivity of the effect. When the researchers silenced MyD88 in melanoma cells, metastatic dissemination was profoundly impaired, yet primary tumor growth was essentially unaffected. This dissociation matters clinically: it suggests that MyD88 is not a generic growth gene whose removal would broadly poison the tumor, but a specific enabler of the dissemination program. Therapeutically, that distinction is attractive, because an intervention targeting metastasis-competent states could in principle reduce the spread of disease without imposing the same evolutionary pressure on bulk tumor growth that drives classic resistance to cytotoxic agents.

To understand what MyD88 was actually doing inside the cells, the team combined genetic silencing and overexpression with transcriptomic profiling and a battery of functional assays covering invasion, adhesion, and interactions with endothelial cells and the extracellular matrix. The picture that emerged was of a protein that rewires melanoma cell transcriptional programs. When MyD88 was depleted, mesenchymal-like invasive features were suppressed and the cells lost metastatic competence. In particular, MyD88 sustains an integrin-mediated adhesion program, a set of surface receptors and associated signaling machinery that anchors cells to their surroundings. Integrins are the molecular velcro that cells use to grip collagen and other matrix components and to cling to the endothelial cells lining blood vessels.

That adhesive capacity turns out to be central to nearly every step of the metastatic cascade. For a melanoma cell to escape a primary tumor, it must invade through surrounding tissue, intravasate into a blood or lymphatic vessel, survive the journey through the circulation, and then extravasate through the vessel wall into a new organ, where it must find purchase in an unfamiliar microenvironment. Each of these transitions demands controlled adhesion: enough grip to pull through tissue and dock on vessel walls, but enough release to let go and move. By enhancing tumor cell interactions with the extracellular matrix and the endothelium, MyD88 supports local invasion, intravasation, extravasation, and ultimately dissemination to distant sites, positioning it as a coordinator of the entire journey rather than a factor acting at a single checkpoint.

The study also addressed a question that has long hovered over metastasis research: how do external environmental cues get translated into stable changes in cell behavior? Tumor cells live in a fluctuating world of inflammatory signals, nutrient scarcity, hypoxia, and tissue damage, and these pressures can induce transient plastic states that favor invasion. The researchers found that multiple environmental stimuli, including genotoxic stress, growth factors, and nutrient deprivation, increase MyD88 expression in melanoma cells. In other words, MyD88 functions as an environmentally responsive node, a sensor that registers hostile conditions and converts them into an adhesive, motile phenotype. This provides a mechanistic bridge between the tumor microenvironment and the intrinsic wiring of the cancer cell, an integration point that had been incompletely understood.

Downstream of these stimuli, the team identified STAT3 signaling as the central pathway driving the integrin-associated adhesive programs. STAT3, a transcription factor with well-documented roles in inflammation-associated cancer, appears to be the conduit through which MyD88 translates environmental stress into changes in gene expression that favor metastasis. This detail is significant because it links a known inflammatory signaling axis to a specific, actionable cellular outcome, and it suggests that the metastasis-competent state is not hard-wired by mutations but actively maintained by signaling that could, in principle, be interrupted.

Single-cell analysis added a layer of resolution that bulk measurements could never provide. Within primary tumors, MyD88 marks a distinct subpopulation of cells characterized by pro-adhesive and pro-metastatic features, effectively flagging the cells most likely to seed new lesions. Consistent with that role, circulating tumor cells isolated from the models were enriched for MyD88 expression and displayed motility- and adhesion-associated transcriptional states, indicating that the cells that make it into the bloodstream carry the MyD88-defined program with them. When the researchers interfered with MyD88, the release of circulating tumor cells dropped and metastatic seeding to distant organs was significantly impaired, closing the loop between the molecular findings and the clinical outcome they are meant to explain.

The implications for treatment are considerable, though tempered by the usual caveats of early-stage research. Because MyD88 is dispensable for primary tumor growth in these models, a therapy aimed at its pathway could act as a metastasis suppressor, potentially useful in the adjuvant setting where the goal is to prevent dormant disease from ever establishing itself. The identification of STAT3 as a downstream effector is especially intriguing given that STAT3 inhibitors have been pursued for years in oncology, and the study offers a rationale for testing them specifically against melanoma dissemination. There are also biomarker implications: MyD88 expression could help identify patients whose tumors harbor a metastasis-competent subpopulation, guiding surveillance and treatment intensity. Any such translation, however, would need to contend with MyD88’s essential role in normal immune function, which makes systemic targeting a delicate proposition.

Conceptually, the study reframes metastasis not as a rare stochastic event but as a regulated, environmentally responsive cell state that can be identified, monitored, and potentially disarmed. By showing that a single adaptor protein links external stress signals, STAT3 activation, integrin-mediated adhesion, and the full arc of the metastatic cascade in NRAS-mutant melanoma, the Milan team has supplied both a mechanistic model and a set of concrete experimental entry points. The work was conducted under institutional and Italian Ministry of Health animal welfare approvals, with patient biopsies collected under informed consent, and the article is available open access for the research community to build upon. As melanoma treatment continues to improve for many patients, understanding why the disease still spreads in others remains one of the field’s most urgent questions, and this study offers a clear, testable answer to part of it.

Subject of Research: The role of the adaptor protein MyD88 in sustaining integrin-mediated adhesion and metastatic competence in NRAS-mutant melanoma

Article Title: MyD88 sustains a metastasis-competent cell state by promoting integrin-mediated adhesion in melanoma

Article References: Marocchi, F., Lafranconi, M., Lazzarini, F., Lotti, F., Mileti, E., Mazzarella, L., Furia, L., Zocchi, A., Bertolini, G., Sozzi, G., Faretta, M., Schaefer, M. H., Melixetian, M., & Lanfrancone, L. (2026). MyD88 sustains a metastasis-competent cell state by promoting integrin-mediated adhesion in melanoma. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03853-w

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03853-w

Keywords: melanoma, metastasis, MyD88, integrin-mediated adhesion, circulating tumor cells, STAT3 signaling, cell plasticity, patient-derived xenograft, NRAS-mutant melanoma, tumor microenvironment, extracellular matrix, endothelial interaction

The technology belongs to a field called acoustofluidics, which exploits the fact that sound waves traveling through a fluid exert forces on suspended particles. When two surface acoustic waves, generated by interdigital transducers etched onto a piezoelectric lithium niobate substrate, meet inside a microchannel, they create a standing pressure field. Particles suspended in that field experience an acoustic radiation force that pushes them toward or away from pressure nodes. Crucially, this force scales strongly with particle volume, so a 15-micrometer cancer cell feels a vastly stronger push than an 80-nanometer particle. The research team exploited exactly this size asymmetry to split their two-component streams into different outlets.

Designing the chip was a careful balancing act. The researchers compared two frequency-scaled geometries numerically before committing to fabrication: one operating at 3.75 megahertz with a 200-micrometer-wide main channel, and a rescaled 5.4-megahertz design with a narrower 137-micrometer channel. Using COMSOL Multiphysics simulations that coupled laminar flow, acoustic fields, and particle tracing, they found that the 3.75-megahertz geometry reached stable outlet assignment at a substantially lower forcing threshold. At the higher frequency, the required boundary velocity jumped roughly sevenfold. The team stresses that this is a system-level result reflecting the coupled influence of channel width, acoustic node placement, interaction length, and residence time, not a simple frequency effect. The lower-threshold 3.75-megahertz design was therefore the one that went to the cleanroom.

The channel geometry itself was dictated by the physics. At 3.75 megahertz, the acoustic half-wavelength in water is approximately 200 micrometers, so the main channel was sized to match, allowing a single transverse pressure node to form at 70 percent of the channel width. The interdigital transducers were defined from the surface acoustic wavelength of 1.0368 millimeters, with finger widths of about 259 micrometers and 35 finger pairs. Inlets and outlets branch off at 15 degrees to preserve smooth hydrodynamic focusing, and the acoustic interaction zone stretches 9 millimeters along the channel, giving cells enough residence time to migrate laterally before the flow splits.

Fabrication combined two independent processes. A silicon wafer was patterned with a 40-micrometer-tall SU-8 master, from which a PDMS microchannel was replica-molded. Meanwhile, titanium and gold electrodes were sputtered and wet-etched onto the lithium niobate substrate. The two layers were aligned so the channel sat squarely within the acoustic aperture, then bonded with oxygen plasma and mounted on a glass support to protect the fragile piezoelectric substrate. The result was a sealed, reusable microchip in which a 1-microliter-per-minute sample stream, hydrodynamically focused by a 10-microliter-per-minute sheath flow, passes through the standing-wave region in single file.

For biological validation, the team used MCF-7 human breast adenocarcinoma cells as tumor-cell models, deliberately switching from their standard DMEM culture medium to RPMI-1640 supplemented with serum and EDTA to suppress the adhesion and aggregation that had caused clogging in preliminary tests. As the nanoscale counterpart, they used cellulose nanofibers of 20 to 50 nanometers, a non-biological model material chosen to represent the size range of extracellular vesicles without claiming to characterize the vesicles themselves. The authors are explicit about this distinction: the experiments establish physical outlet assignment in a controlled model system, not clinical extracellular-vesicle isolation.

The experimental results are striking. At 20 volts peak-to-peak, target-outlet recovery was 152 of 153 cells for a 51-cell input, 316 of 318 for 106 cells, and 735 of 756 for 252 cells, corresponding to run-level means between 97.2 and 99.4 percent with coefficients of variation no greater than 1.63 percent. Post-processing viability, measured by trypan blue staining, ranged from about 82 to 89 percent. Paired no-acoustic controls at zero voltage confirmed that the redirection was genuinely actuation-dependent: without sound, every single cell followed the carrier-flow outlet, while passage through the chip alone preserved viability above 98 percent. Voltage screening at 18 volts showed incomplete migration, mapping out the lower edge of the operating window.

The cellulose nanofibers behaved exactly as the size-scaling argument predicted. Across nine runs at 250, 500, and 1000 micrograms per milliliter, the nanofiber suspension consistently exited through the carrier-flow-directed outlet, verified by visual turbidity and centrifugation-based pellet assessment, while the target outlet stayed clear. Mixed-sample testing then revealed an important boundary. At 250 micrograms per milliliter, cell recovery and viability matched the cell-only results. But at 1000 micrograms per milliliter, although recovery remained high at 95 percent, post-processing viability collapsed to roughly 36 percent, a nearly 49-percentage-point drop that the authors report as a descriptive effect without assigning a mechanism, since no nanofiber-only cell-exposure control was included.

Thermal management, a known concern for living-cell acoustofluidics, was addressed with contact thermometry at the glass surface adjacent to the channel. The maximum recorded temperature across the actuation range was 38.5 degrees Celsius, comfortably below levels typically considered harmful to cells, although the authors note this characterizes local surface response rather than the full intrachannel temperature field. Notably, all 38 experimental runs were completed on a single reusable device using a standardized cleaning protocol of PBS and ethanol flushes, with no observed clogging, leakage, or delamination, demonstrating operational stability that is often absent from single-use microfluidic demonstrations.

The study is candid about its limits. All results come from one fabricated chip, so device-to-device reproducibility remains untested; the nanofiber endpoint is qualitative rather than a quantitative recovery measurement; and MCF-7 cells do not reproduce the rarity and heterogeneity of patient-derived circulating tumor cells. The authors position the platform as a downstream model-system module with a clearly defined operating window, a deliberate contrast to claims of whole-blood processing in a single device. Within that scope, the work delivers something the field has lacked: a single experimentally validated regime linking frequency-scaled geometry selection, hydrodynamic controls, low-count recovery, viability, thermal screening, and nanoscale loading boundaries. If future iterations can transfer this operating logic to biologically characterized extracellular vesicles and clinical samples, sound-driven chips of this kind could become a label-free workhorse for the sample-preparation bottleneck that currently constrains liquid biopsy.

Subject of Research: Size-selective surface acoustic wave acoustofluidic separation of MCF-7 tumor-cell models from cellulose-nanofiber suspensions in a reusable microchip

Article Title: Size-selective SAW acoustofluidic microchip for separating MCF-7 tumor-cell models from cellulose-nanofiber suspensions

Article References: Moghimi, M., Jalali, N., & Abbasvandi, F. (2026). Size-selective SAW acoustofluidic microchip for separating MCF-7 tumor-cell models from cellulose-nanofiber suspensions. Results in Engineering, 32, Article 113494. https://doi.org/10.1016/j.rineng.2026.113494

Image Credits: AI Generated

DOI: 10.1016/j.rineng.2026.113494

Keywords: acoustofluidics, surface acoustic waves, liquid biopsy, circulating tumor cells, MCF-7 cells, cellulose nanofibers, microfluidics, label-free separation, extracellular vesicles, piezoelectric transducers, cell viability, lab-on-a-chip

The drug at the center of the story is quercetin, a polyphenolic compound found in onions, apples, and many other foods. For years, quercetin has attracted attention for its ability to interfere with cancer cell migration, invasion, and epithelial-to-mesenchymal transition, the biological program that allows stationary epithelial tumor cells to loosen their anchors and drift through tissue. Laboratory studies have repeatedly shown that quercetin can suppress metastatic behavior across prostate, ovarian, breast, and glioblastoma models. Yet the compound has a stubborn flaw that has kept it out of serious clinical consideration: poor bioavailability. Free quercetin is poorly soluble, unstable, and rapidly cleared, meaning that very little of an administered dose ever reaches the tumor in an active form.

The research team, led by V. Jenitha and colleagues at Karunya Institute of Technology and Sciences in Coimbatore, tackled that limitation with a liposomal formulation the group calls Lipo-Que. Liposomes are microscopic spherical vesicles built from phospholipid bilayers, the same structural motif that encloses living cells. By dissolving quercetin within these lipid shells, the researchers shield the fragile molecule from degradation, improve its circulation time in the bloodstream, and enhance its delivery to tumor tissue. The formulation builds on the team’s earlier work, published in the Journal of Drug Delivery Science and Technology, in which they optimized the cholesterol content of the liposomes for intravenous administration and demonstrated the formulation’s safety profile in mice.

To test whether the nano-packaged quercetin could actually restrain metastasis, the researchers turned to a well-established mouse model of lung cancer induced by benzo(a)pyrene, a potent carcinogen found in tobacco smoke and charred foods. Benzo(a)pyrene drives lung tumor formation through well-characterized mutagenic and inflammatory pathways, and it also promotes metastatic signaling through mechanisms involving nuclear factor kappa B, making it a demanding test bed for any anti-metastatic drug. Animals with induced lung cancer were treated with either free quercetin or the liposomal version, and the outcomes were compared across a battery of in vitro and in vivo assays.

The results were striking. In cell migration assays conducted in the laboratory, Lipo-Que inhibited the movement of cancer cells far more effectively than free quercetin, with the difference reaching statistical significance at the stringent threshold of P less than or equal to 0.001. In the living animals, the liposomal formulation produced a marked reduction in lung tumor burden, the number and extent of tumor foci scattered through the lung tissue. Most dramatically, the treatment achieved complete suppression of hepatic metastasis, meaning that the livers of Lipo-Que-treated mice showed no evidence of the cancer colonies that had taken hold in untreated and free-quercetin-treated animals. For a disease whose lethality is defined by spread to distant organs, that single finding carries considerable weight.

But the second half of the study may prove to be its most influential contribution. Measuring whether an anti-metastatic drug works has traditionally required invasive procedures: surgical biopsy of tumor tissue, histopathological examination, or terminal analysis of organs. The researchers instead asked whether the body’s own fluids could tell the story. Liquid biopsy, the analysis of tumor-derived cells and biomarkers circulating in blood, bronchoalveolar lavage fluid, or tracheal secretions, has gained momentum in oncology as a way to detect and monitor cancer without a scalpel. Circulating tumor cells shed from primary tumors and metastatic sites can be captured and characterized, and their surface markers reveal a great deal about the state of the disease.

The team focused on a protein called EpCAM, the epithelial cell adhesion molecule, which is overexpressed on many epithelial-derived cancer cells and is widely used to identify metastatic tumor cells in fluid samples. Using fluorescence-activated cell sorting, a flow cytometry technique that quantifies and isolates cells bearing specific surface markers, the researchers counted EpCAM-positive and epithelium-like cells in the liquid biopsy samples of each treatment group. In the mice receiving Lipo-Que, these populations dropped significantly, again at the P less than or equal to 0.001 level, indicating that the treatment was not merely shrinking tumors but reducing the pool of cells capable of seeding new colonies.

The truly novel step came next. Rather than discarding the harvested cells after counting them, the researchers cultured them outside the body for seven days, an ex vivo approach that turns a diagnostic snapshot into a functional test. Cells from untreated cancer-bearing mice proliferated robustly in culture, adhering to the growth surface and expanding steadily, a signature of viable, aggressive metastatic potential. Cells from mice treated with free quercetin showed some restraint, but the inhibition was inconsistent. Cells from the Lipo-Que group, by contrast, displayed sustained growth inhibition from the very first day of culture through day seven, and the mean number of adherent cells was significantly reduced. Under the microscope, the treated animals’ cells showed shrunken, fragmented morphological features characteristic of apoptosis, the controlled cell death program that cancer cells must evade to survive dissemination.

This combination of cell morphology analysis, EpCAM quantification, and ex vivo culture constitutes what the authors describe as therapeutic indexing, a functional, minimally invasive platform for assessing anti-metastatic efficacy as treatment unfolds. The concept has immediate appeal for precision oncology. If a patient’s circulating tumor cells can be harvested, cultured, and challenged in the laboratory, clinicians could in principle gauge whether a therapy is suppressing metastatic potential within days rather than waiting months for imaging scans to reveal whether new lesions have appeared. The approach also sidesteps a known blind spot of EpCAM-based detection alone, since tumor cells undergoing epithelial-to-mesenchymal transition can shed the marker; pairing molecular phenotyping with functional culture provides a more complete picture of residual metastatic risk.

Cautious optimism is the appropriate posture. The findings come from a carcinogen-induced mouse model, and the long road from rodent studies to human trials is littered with therapies that succeeded in animals but failed in patients. Quercetin itself has shown biphasic effects at different concentrations in some studies, and questions about optimal dosing, long-term safety, and delivery to human tumors remain open. Nevertheless, the study demonstrates two ideas worth watching. First, that nanotechnology can rescue a dietary compound with genuine anti-metastatic biology from its own pharmacological weaknesses, converting it into a targeted therapeutic candidate. Second, that the fluid a patient already carries, whether blood or airway lavage, can be transformed into a living laboratory where the effectiveness of that therapy is tested directly on the patient’s own cancer cells. If those two principles survive translation, the management of metastatic lung cancer, the deadliest phase of the world’s deadliest cancer, could become measurably more responsive, more personal, and far less invasive.

Subject of Research: Liposomal quercetin nanotherapy and liquid biopsy-based functional assessment of metastasis suppression in experimental lung cancer

Article Title: Liquid biopsy cell analysis and ex vivo culture as effective methods of therapeutic indexing of metastasis in B[a]P-induced lung cancer mice for an active targeted quercetin therapy

Article References: Jenitha, V., Wilson, D. D., Raj, G. M., Kokelavani, N. B., Srividhya, M., Nandana, V., Sundaram, V., Harsha, S., & Grace, V. M. B. (2026). Liquid biopsy cell analysis and ex vivo culture as effective methods of therapeutic indexing of metastasis in B[a]P-induced lung cancer mice for an active targeted quercetin therapy. 3 Biotech, 16(11), Article 459. https://doi.org/10.1007/s13205-026-05071-9

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05071-9

Keywords: lung cancer, liquid biopsy, quercetin, liposomes, nanomedicine, metastasis, EpCAM, ex vivo culture, circulating tumor cells, drug delivery, precision oncology, benzo(a)pyrene

The device at the heart of the study is a deterministic lateral displacement, or DLD, microfluidic chip, a technology first demonstrated in the early 2000s. A DLD device is essentially a dense forest of tiny pillars arranged in tilted rows. As blood flows through the array, particles smaller than a critical size follow the fluid streamlines and pass straight through, while particles larger than that threshold are nudged sideways each time they collide with a pillar. Because the displacement is deterministic rather than diffusive, the device can continuously sort cells by size without any chemical labels, antibodies, or centrifugation. That makes DLD attractive for liquid biopsies, where the goal is to pluck tumor cells from a blood sample while leaving red blood cells and white blood cells behind.

The catch is that DLD performance depends on a tangle of coupled variables. The gap between pillars, the tilt angle of the post array, and the flow rate of the sample all interact in nonlinear ways to determine how far a target cell is displaced laterally. A small change in one parameter can shift the effective critical diameter that separates tumor cells from blood cells, and a change in another can amplify or suppress that effect. Traditionally, engineers have navigated this design space by trial and error, running simulation after simulation or fabricating chip after chip. Each evaluation is computationally expensive, and brute-force parametric sweeps offer little insight into how the parameters actually interact with one another.

The research team, led by Sadia Anjum Mim and corresponding author Xiaolin Chen, with Mohammed Raihan Uddin as a co-author, replaced that brute-force search with Bayesian optimization. The approach treats each simulation of the DLD device as an expensive black-box function whose output is the lateral displacement of the target particle. Instead of blindly sampling the design space, Bayesian optimization builds a Gaussian process surrogate model, a probabilistic statistical model that learns the relationship between the design variables and the displacement response. The Gaussian process not only predicts the displacement for any candidate design but also quantifies how uncertain that prediction is. An acquisition function then uses both the prediction and the uncertainty to decide where to sample next, balancing exploration of poorly understood regions against exploitation of promising ones.

The team used three design variables in the optimization: the pillar gap size, the tilt parameter of the post array, and the flow rate. Each candidate design was evaluated with detailed numerical simulations of the fluid and particle dynamics, and the results fed back into the surrogate model, which grew more accurate with every iteration. The final Gaussian process model achieved a coefficient of determination, R-squared, of 0.9873 on an independent validation dataset, with a mean absolute error of just 1.24 micrometers. In practical terms, the surrogate could predict how far a target cell would be pushed sideways by a given chip design with remarkable fidelity, without needing to run the full simulation every time.

The efficiency gains were striking. When the researchers compared Bayesian optimization against an Evolution Strategy benchmark, the Bayesian approach needed 67.2 percent fewer evaluations to identify the best-performing design within the prescribed design space and cut the time to solution by 80.0 percent. It also outperformed Genetic Algorithms, Differential Evolution, Particle Swarm Optimization, and conventional parametric sweeps. Because each evaluation of the underlying simulation is costly, reducing the number of required evaluations translates directly into days or weeks of saved computation, and it opens the door to exploring design spaces that would be intractable with exhaustive methods.

The winning design identified by the optimizer produced a target-particle lateral displacement of 75.51 micrometers. Follow-up analyses of particle size and outlet regions revealed an effective critical diameter of approximately 11.4 micrometers, a threshold that cleanly separates the investigated non-small-cell lung cancer CTC surrogate from smaller blood-cell-relevant background particles. The team demonstrated distinct collection of the target and background particles across three different release positions, meaning the separation remained robust regardless of where cells entered the device. That kind of positional robustness matters in a real clinical sample, where cells arrive at the chip inlet distributed across the full width of the channel rather than in a tidy single stream.

Beyond finding a single optimal design, the Gaussian process surrogate turned out to be a rich analytical tool in its own right. Because the model covers the entire design space, it enables response-surface mapping, which visualizes how displacement varies across combinations of parameters. It also supports global sensitivity analysis, which quantifies how much each design variable contributes to the output. The analysis identified the post-array tilt parameter as the dominant factor governing target-particle lateral displacement, while the flow rate was found to interact strongly with the geometric variables. That interaction is precisely the kind of insight that trial-and-error approaches miss, and it gives device designers a physical intuition about which knobs matter most and how they couple.

The framework also incorporates uncertainty quantification, a feature that distinguishes it from many purely data-driven design pipelines. Uncertainty analysis confirmed that the optimized device maintains stable performance under perturbations, meaning that small manufacturing imperfections or operating fluctuations are unlikely to destroy the separation quality. For microfluidic devices that must eventually be fabricated at scale and operated outside pristine laboratory conditions, this reliability-aware perspective is essential. A design that performs brilliantly only at one exact point in parameter space is of limited clinical value; one that tolerates realistic variation is far more likely to survive the journey from simulation to bedside.

The broader implications extend past cancer diagnostics. DLD devices have been used to separate parasites from blood, fractionate blood components, and sort particles across a wide range of sizes, and the optimization framework described here is general enough to be applied to any of these applications. By making the design process faster, more interpretable, and more reliable, Bayesian optimization could accelerate the development of an entire family of label-free cell-sorting chips. For liquid biopsy, in particular, the prospect of a cheap, antibody-free, continuously operating chip that reliably isolates circulating tumor cells is compelling, and this study demonstrates that intelligent algorithmic design, rather than exhaustive manual tuning, may be the fastest route to getting there. The work was supported in part by the National Science Foundation under Grant No. 2243980.

Subject of Research: Machine learning-driven optimization of microfluidic deterministic lateral displacement devices for label-free circulating tumor cell separation

Article Title: Bayesian optimization of deterministic lateral displacement devices for circulating tumor cell separation

Article References: Mim, S. A., Uddin, M. R., & Chen, X. (2026). Bayesian optimization of deterministic lateral displacement devices for circulating tumor cell separation. Biomedical Microdevices, 28(4), Article 72. https://doi.org/10.1007/s10544-026-00856-4

Image Credits: AI Generated

DOI: 10.1007/s10544-026-00856-4

Keywords: Bayesian optimization, Gaussian process, deterministic lateral displacement, circulating tumor cells, microfluidics, liquid biopsy, surrogate modeling, cell separation, uncertainty quantification, sensitivity analysis, biomedical microdevices, machine learning

The research team, working at Rice University with collaborators at Vanderbilt University Medical Center, exposed two well-known prostate cancer cell lines to repeated pulses of high-intensity fluid shear stress reaching 3950 dyn/cm2, a level far beyond anything previously tested in sustained experiments. For context, venous blood flow typically imposes forces of roughly 0.5 to 4 dyn/cm2, arterial flow ranges from 4 to 30 dyn/cm2, and turbulent regions near arterial bifurcations or inside the heart can briefly generate pulses on the order of 1000 dyn/cm2. The researchers used a syringe pump to perfuse cells through a fine 30-gauge needle at high speed, producing a brief pulse lasting just over a millisecond, with each pulse delivered two minutes apart. Over four to five months, the cells endured approximately sixty of these treatments, with the number of pulses per session gradually increased.

The two cell lines told strikingly different stories. LNCaP cells, originally derived from a lymph node metastasis, showed limited innate resistance and could only tolerate up to ten shear pulses per treatment. PC3 cells, which came from a bone metastasis and therefore plausibly experienced circulatory forces in the patient from whom they were isolated, proved innately tough, maintaining viability above eighty percent even after twenty pulses. By repeatedly selecting the survivors, the team generated what they call mechanoresistant, or MR, populations. After ten pulses, the mechanoresistant LNCaP cells retained nearly seventy percent viability, while unmodified parental cells dropped to under thirty-eight percent. The PC3 cells, already robust, showed that innate resistance alone does not capture the full picture of how metastatic cells adapt.

Under the microscope, the mechanoresistant PC3 cells revealed a fascinating physical transformation. They became significantly smaller, less granular, and less spread out when attached to a surface, adopting features consistent with an amoeboid morphology, a rounded, highly deformable state that has been linked to enhanced metastatic capacity in several cancer types. Analysis of epithelial and mesenchymal markers showed that these cells occupied a hybrid state, expressing both E-cadherin and vimentin, rather than committing fully to either program. This plasticity may be exactly what allows circulating tumor cells to survive the mechanical gauntlet of the bloodstream and then squeeze back out of vessels to seed new tumors, a process during which many cells are known to undergo partial transitions between epithelial and mesenchymal states.

The cell cycle findings were equally unexpected. Previous studies had generally shown that fluid shear stress drives tumor cells into cell cycle arrest and promotes stress-induced death. Here, the mechanoresistant cells did the opposite. Twenty-four hours after shear exposure, the PC3 mechanoresistant cells showed a significantly elevated fraction of cells in S phase, the DNA replication stage, and a corresponding reduction in the G1 phase, indicating accelerated progression through the cycle rather than arrest. Both mechanoresistant lines also displayed elevated expression of Piezo1, a calcium-permeable mechanosensitive ion channel that has previously been implicated in prostate cancer progression, migration, and proliferation. The researchers found that Piezo1 levels correlated positively with proliferative activity, suggesting a mechanistic link between mechanical sensing and the growth behavior of these adapted cells.

Bulk RNA sequencing, performed after roughly sixty shear treatments, confirmed that the mechanoresistant cells had acquired genuinely distinct molecular identities, clustering separately from both parental cells and higher-passage controls designed to rule out artifacts of long-term culture. Among the significantly upregulated genes in the PC3 mechanoresistant cells, one stood out: CALB2, which encodes the calcium-binding protein calretinin. Calretinin buffers intracellular calcium levels, placing it in a prime position to modulate signaling downstream of mechanosensitive channels like Piezo1. Quantitative PCR and Western blotting confirmed the elevated mRNA and protein expression, and the finding carried particular weight because calretinin had never before been examined in the context of fluid shear stress in any cancer.

To probe calretinin’s role in human disease, the team measured the protein in prostate tissue microarrays. Calretinin expression was highest in adenocarcinoma and metastatic samples compared with normal adjacent tissue and samples from patients with hyperplasia or prostatitis, and in paired comparisons, four of six patients showed elevated calretinin in tumor tissue relative to their healthy neighbors. Mining large clinical datasets, including the TCGA prostate adenocarcinoma cohort, revealed that high CALB2 expression correlated with reduced overall survival, although the association did not reach statistical significance in that particular analysis. Intriguingly, CALB2-high outlier tumors appeared across all Gleason grades, suggesting that calretinin elevation may reflect a patient-specific transcriptional state rather than a simple marker of tumor aggressiveness. The team also found that CALB2 expression correlated with DGK1, a lipid signaling gene, and with EPB41L3, a tumor suppressor, hinting at a broader co-expression network tied to membrane and cytoskeletal biology.

The decisive experiment came with genetic deletion. Using lentiviral CRISPR constructs, the researchers knocked out CALB2 in their PC3 lines and re-exposed the cells to twenty shear pulses. The result was dramatic and highly specific: while parental and mechanonaive knockout cells barely noticed the treatment, the mechanoresistant cells lost their hard-won protection, with viability plummeting to roughly thirty-six percent after twenty pulses. The knockout cells also showed reduced proliferative activity, with a larger fraction displaying low Ki67 expression. Because parental cells never depended on CALB2 for shear survival, the gene appears to be a genuine acquired mechanoresistance factor, a molecular prop that the adapted cells came to rely upon. This makes CALB2 the first gene to be functionally validated as a mediator of resistance to high-intensity fluid shear stress through repeated exposure experiments.

In vivo work reinforced the picture. In a pilot subcutaneous study, mechanoresistant cells produced higher tumor burden than parental controls, showing that their adapted traits persisted outside the dish. The team then performed an orthotopic model, surgically implanting luciferase-labeled PC3 cells into the prostate of immunodeficient mice and tracking tumor growth by bioluminescence for twelve weeks. Mechanoresistant tumors grew slightly faster during the first nine weeks, and calretinin levels in the resected tumors were highest in the mechanoresistant group, mirroring the in vitro findings, though the magnitude of the difference was more modest, likely reflecting the complexity of the tumor microenvironment. Few metastases were detected in any group, a limitation the authors attribute to the Matrigel used for engraftment and the severe immunodeficiency of the mouse strain.

The implications reach beyond prostate cancer. Circulating tumor cell survival remains the least studied stage of metastasis, partly because these cells spend an estimated twenty-five to thirty minutes in the bloodstream and are extraordinarily difficult to capture and study. By building the first stable mechanoresistant cancer cell lines, the researchers have created a durable experimental platform for dissecting how tumor cells withstand hemodynamic forces, a question that touches on cytoskeletal remodeling, membrane repair, calcium signaling, and ion channel biology all at once. Calretinin itself lacks well-defined drug-binding pockets, so direct pharmacological targeting may be difficult, and compensatory calcium buffers such as calmodulin could blunt any single-gene strategy. But the discovery that a calcium-buffering protein underpins mechanical survival opens a concrete therapeutic avenue: combining mechanosensitive channel inhibitors, such as the Piezo1 blocker GsMTx4, with existing apoptosis-triggering agents like TRAIL could exploit the very adaptations that make metastatic cells lethal. For the roughly seventy percent drop in five-year survival that accompanies distant prostate cancer metastasis, understanding and disrupting this mechanical armor may prove to be a critical step forward.

Subject of Research: Mechanoresistance and the role of CALB2 in metastatic prostate cancer cell survival under fluid shear stress

Article Title: CALB2 is a Mechanoresistance Gene in Metastatic Prostate Cancer

Article References: Fabiano, A. R., Luo, A. C., Taufalele, P., Dombroski, J. A., Aalaei, E., Rowland, S. J., Cantú, M. S., Carter, A. T., Knoblauch, S. V., Reinhart‐King, C. A., & King, M. R. (2026). CALB2 is a Mechanoresistance Gene in Metastatic Prostate Cancer. Advanced Science, 13(55), Article e76535. https://doi.org/10.1002/advs.76535

Image Credits: AI Generated

DOI: 10.1002/advs.76535

Keywords: prostate cancer, metastasis, circulating tumor cells, fluid shear stress, CALB2, calretinin, mechanotransduction, Piezo1, CRISPR knockout, RNA sequencing, orthotopic mouse model, Advanced Science

A research team led by Professor Xiaochun Li of the Institute of Biomedical Precision Testing and Instrumentation at Taiyuan University of Technology, working in collaboration with Director Lizhong Zhang of Shanxi Bethune Hospital, has now unveiled a platform that tackles both halves of this problem at once. Writing in the journal Biomedical Analysis, the team describes a system that pairs a specially engineered microfluidic chip with a deep learning model to enrich and identify rare tumor cells without the use of molecular labels. Dr. Weizhi Liu of Taiyuan University of Technology, Professor Li, and Director Zhang serve as co-corresponding authors, with master’s student Junyi Ouyang as first author and Dr. Haiqin Li also contributing to the study. The work, published under the title Label-free Enrichment and Identification of Circulating Tumor Cells Integrating Inertial Microfluidics and Deep Learning, represents a proof-of-concept demonstration of how physics and artificial intelligence can be woven together into a single analytical pipeline.

The first stage of the platform addresses the separation problem, and it does so by exploiting the most basic physical difference between tumor cells and blood cells: their size. Most conventional CTC isolation techniques depend on antibodies that bind to specific molecules on the surface of tumor cells, most famously the epithelial marker EpCAM. This strategy has a fundamental weakness. Tumor cells are extraordinarily diverse, and different subpopulations of CTCs, particularly those that have undergone a transition toward a more invasive state, may shed or never express the very markers the technology is designed to detect. Cells that lack the marker simply slip through the filter, taking their secrets with them. Label-free approaches sidestep this limitation by relying on intrinsic physical characteristics such as cell diameter and deformability, which are far harder for a cell to disguise.

The chip designed by the Taiyuan team is a spiral microfluidic device containing carefully engineered contraction-expansion structures along its length. The underlying principle is inertial microfluidics, a technique in which fluid flowing through narrow channels at high speed generates lift forces that push cells into predictable equilibrium positions across the channel cross-section. Because CTCs are generally larger than blood cells, with typical diameters of roughly 12 to 25 micrometers compared with 7 to 12 micrometers for white blood cells and 6 to 8 micrometers for red blood cells, each cell population experiences a different balance of forces as it travels through the microchannel. The contraction-expansion geometry amplifies these differences, steering tumor cells and blood cells into separate flow paths so that tumor cells can be collected at a dedicated outlet without any dependence on surface markers.

The team validated the separation concept through computer simulations and laboratory experiments before testing it on artificial blood samples spiked with MCF-7 breast cancer cells and white blood cells. The results were striking. Tumor cells were concentrated at the central outlet while the majority of blood cells were routed toward the side outlets. Quantitatively, the system achieved an MCF-7 cell recovery rate of 89.2 percent, with a standard deviation of 3.1 percent, and a white blood cell removal rate of 86.9 percent, with a standard deviation of 1.4 percent. Perhaps most tellingly, the proportion of tumor cells in the collected fraction rose from 9 percent before separation to 38 percent after enrichment. That fourfold increase in purity dramatically reduces the background the identification stage must contend with, and it does so without staining, labeling, or chemically altering the cells in any way.

Separation, however, is only half the battle. Once the enriched sample has been collected, researchers still face the question of which cells among the mixture are truly tumor cells. In many existing workflows this determination requires fluorescent staining or antibody-based labeling, which adds processing steps, consumes time, requires specialized reagents and equipment, and can compromise the viability or molecular integrity of the very cells researchers hope to study downstream. Fluorescence-based identification also ties the analysis to specific markers, reintroducing at the detection stage the same bias that label-free separation was designed to eliminate. The Taiyuan team’s answer to this dilemma is a deep learning model based on the YOLOv8 architecture, trained to recognize tumor cells directly from ordinary bright-field microscope images, the kind of imagery any standard laboratory microscope can produce.

YOLOv8, whose name stands for You Only Look Once, is a family of object detection models known for speed and accuracy in computer vision tasks. During the development of the platform, fluorescence images were used to establish the ground-truth identity of different cell types and to support the annotation of training data, but once training was complete the model performed all recognition using bright-field images alone. This is a meaningful distinction from many image-analysis approaches that require individual cells to be manually isolated or segmented before classification. YOLOv8 can locate, classify, and count cells directly within complete microscope images, treating the identification task as a single integrated detection problem rather than a multi-step pipeline vulnerable to accumulated error.

The performance figures reported for the identification stage are impressive for a label-free method. The model achieved 96.0 percent overall accuracy in distinguishing tumor cells from non-tumor cells, with precision and recall both at 94.6 percent and specificity at 95.4 percent. In practical terms, this means the system correctly identifies nearly all tumor cells present while rarely misclassifying blood cells as tumor cells, a balance that is critical when the starting population is so heavily skewed toward blood cells. The results demonstrate that artificial intelligence can extract subtle morphological information from standard bright-field images, information that would previously have required fluorescent labeling to access, thereby reducing cost, complexity, and the risk of damaging precious clinical samples.

By combining physical cell sorting with artificial intelligence, the platform addresses the two major bottlenecks that have constrained CTC analysis: finding rare tumor cells in a complex blood environment and recognizing them accurately after enrichment. The label-free workflow may simplify sample processing and, because the cells are never stained or chemically modified, help preserve their integrity for downstream applications such as single-cell sequencing and drug susceptibility testing. Those applications matter enormously, since a viable CTC captured intact can reveal the genetic mutations driving a patient’s tumor and predict which therapies are likely to work before any drug is administered. More broadly, the study illustrates how the marriage of microfluidic technology and deep learning can open new possibilities for analyzing rare biological cells of many kinds, not only tumor cells.

The researchers are careful to frame the current work as a proof of concept rather than a finished clinical tool. The platform was validated using MCF-7 cell lines and artificial blood samples rather than patient-derived clinical samples, and the enrichment and recognition modules have not yet been fully integrated into a single automated system. Future studies, the team says, will focus on evaluating additional tumor types and real patient samples while improving system integration and automation. Corresponding author Xiaochun Li summarized the motivation plainly, noting that the challenge of circulating tumor cell analysis is not only finding these rare cells but also identifying them accurately after separation, and that by combining microfluidics with artificial intelligence the team hopes to provide a simpler and more flexible approach for label-free CTC analysis and future downstream applications. If subsequent validation in clinical samples confirms these early results, the day when a routine blood draw can expose the hidden travelers of metastatic cancer may be considerably closer than it once seemed.

Subject of Research: Label-free detection of circulating tumor cells using inertial microfluidics and deep learning

Article Title: A tiny chip and AI team up to find hidden tumor cells in blood

Article References: A tiny chip and AI team up to find hidden tumor cells in blood. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: circulating tumor cells, liquid biopsy, microfluidics, inertial microfluidics, deep learning, YOLOv8, label-free detection, cancer diagnostics, bright-field imaging, cell sorting, MCF-7, biomedical analysis